News | January 20, 2026
Alto Neuroscience bags new US patent for depression drug ALTO-207
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The move strengthens GBL’s clinical-stage presence in the United States
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
While Merck can appeal, Halozyme said it expects the order to hold
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
Subscribe To Our Newsletter & Stay Updated
